Source comparison
Melanotan 1 vs 2: Published Research and Clinical Evidence
The melanotan 1 vs 2 comparison is underscored by a significant difference in published research depth. Melanotan 1 (afamelanotide) has the most robust clinical evidence of any melanocortin tanning peptide, supported by Phase II and Phase III clinical trials t
This comparison does not assign a generated winner or score.
- The melanotan 1 vs 2 comparison is underscored by a significant difference in published research depth. Melanotan 1 (afamelanotide) has the most robust clinical evidence of any melanocortin tanning peptide, supported by Phase II and Phase III clinical trials that led to EU regulatory approval as Scenesse. A landmark randomized controlled trial published in the New England Journal of Medicine (2015) enrolled 74 erythropoietic protoporphyria subjects and demonstrated that afamelanotide implant (16mg) significantly increased pain-free sun exposure time — with treated subjects gaining a median 69.4 hours of direct sun exposure versus 40.8 hours for placebo over a six-month period, a statistically significant improvement (p=0.04). The safety profile showed only mild injection site reactions as meaningful adverse events.
- For melanotan 2, published research is more limited due to its non-approved status. A frequently cited early study by Dorr et al. (1996) demonstrated dose-dependent tanning in human subjects at doses of 0.01 to 0.16 mg/kg, with nausea being the most commonly reported adverse effect at higher doses. Research comparing MC4R agonism — the mechanism melanotan 2 activates for libido effects — has been more extensively studied through bremelanotide (PT-141), which is a related compound. This broader melanocortin receptor literature informs researchers studying melanotan 2’s non-tanning pathways. In the melanotan 1 vs 2 literature review, afamelanotide has substantially more peer-reviewed clinical data.
- A 2010 Phase II trial from the University of Arizona documented afamelanotide’s tolerability across 45 subjects, with 93% of participants experiencing measurable increases in skin pigmentation within two weeks of administration. Adverse events were predominantly injection site reactions (grade 1-2) with no serious adverse events reported. This body of research — combined with post-marketing safety surveillance from Scenesse’s commercial use — gives researchers a substantially more complete picture when evaluating melanotan 1 vs 2 from a documented evidence standpoint. Researchers studying melanotan 2 should also consult the published melanocortin receptor pharmacology literature to understand the broader multi-receptor effects.